GSK's China Misadventures Put Heat On Foreign Drug Trials
The recently revealed compliance failures at GlaxoSmithKline PLC's research center in China could convince the U.S. Food and Drug Administration, already wary of foreign clinical trials, to enhance its oversight of...To view the full article, register now.
Already a subscriber? Click here to view full article